4/3
12:29 pm
roiv
Arbutus Biopharma jumps after patent victory in fight with Moderna [Seeking Alpha]
Medium
Report
Arbutus Biopharma jumps after patent victory in fight with Moderna [Seeking Alpha]
4/3
12:12 pm
roiv
Roivant Sciences Ltd. (NASDAQ: ROIV) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $16.00 to $18.00. They now have a "buy" rating on the stock.
Medium
Report
Roivant Sciences Ltd. (NASDAQ: ROIV) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $16.00 to $18.00. They now have a "buy" rating on the stock.
4/3
08:08 am
roiv
Roivant Sciences Ltd. (NASDAQ: ROIV) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $14.00 to $15.00. They now have a "buy" rating on the stock.
Medium
Report
Roivant Sciences Ltd. (NASDAQ: ROIV) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $14.00 to $15.00. They now have a "buy" rating on the stock.
4/3
08:08 am
roiv
Roivant Sciences Ltd. (NASDAQ: ROIV) had its price target raised by analysts at HC Wainwright from $17.00 to $18.00. They now have a "buy" rating on the stock.
Medium
Report
Roivant Sciences Ltd. (NASDAQ: ROIV) had its price target raised by analysts at HC Wainwright from $17.00 to $18.00. They now have a "buy" rating on the stock.
4/2
02:48 pm
roiv
Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study [Yahoo! Finance]
Low
Report
Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study [Yahoo! Finance]
4/2
07:05 am
roiv
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million [Yahoo! Finance]
Low
Report
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million [Yahoo! Finance]
4/2
07:00 am
roiv
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
Low
Report
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
3/26
06:22 pm
roiv
Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
Low
Report
Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
3/25
01:01 pm
roiv
Roivant Sciences Ltd. (NASDAQ: ROIV) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $23.00 price target on the stock.
Low
Report
Roivant Sciences Ltd. (NASDAQ: ROIV) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $23.00 price target on the stock.
3/18
04:02 pm
roiv
Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success [Seeking Alpha]
Low
Report
Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success [Seeking Alpha]
3/8
10:14 am
roiv
Dermavant Presents New Data on Treatment of Patients with Skin of Color from ADORING 1 and 2 Phase 3 Pivotal Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting [Yaho
Low
Report
Dermavant Presents New Data on Treatment of Patients with Skin of Color from ADORING 1 and 2 Phase 3 Pivotal Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting [Yaho
3/5
07:45 am
roiv
S&P 500 Futures Fall in Premarket Trading; GitLab, Albemarle Lag [MarketWatch]
Medium
Report
S&P 500 Futures Fall in Premarket Trading; GitLab, Albemarle Lag [MarketWatch]
3/1
07:07 am
roiv
Dermavant to Present New ADORING Data Including Treatment of Patients with Skin of Color from Phase 3 Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting [Yahoo! Fina
Medium
Report
Dermavant to Present New ADORING Data Including Treatment of Patients with Skin of Color from Phase 3 Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting [Yahoo! Fina
2/15
07:17 am
roiv
Roivant Sciences Ltd. (NASDAQ: ROIV) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $17.00 price target on the stock.
Low
Report
Roivant Sciences Ltd. (NASDAQ: ROIV) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $17.00 price target on the stock.
2/15
02:55 am
roiv
Do You Think the Management of Roivant Sciences (ROIV) Can Create Value? [Yahoo! Finance]
Low
Report
Do You Think the Management of Roivant Sciences (ROIV) Can Create Value? [Yahoo! Finance]
2/14
06:29 pm
roiv
Roivant Sciences Ltd. (NASDAQ: ROIV) was upgraded by analysts at TheStreet from a "d" rating to a "c+" rating.
Low
Report
Roivant Sciences Ltd. (NASDAQ: ROIV) was upgraded by analysts at TheStreet from a "d" rating to a "c+" rating.
2/14
12:16 pm
roiv
Roivant Sciences Ltd. (NASDAQ: ROIV) had its price target lowered by analysts at HC Wainwright from $18.00 to $17.00. They now have a "buy" rating on the stock.
Low
Report
Roivant Sciences Ltd. (NASDAQ: ROIV) had its price target lowered by analysts at HC Wainwright from $18.00 to $17.00. They now have a "buy" rating on the stock.
2/14
09:23 am
roiv
Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2023 Earnings Call Transcript [Yahoo! Finance]
2/14
08:10 am
roiv
Dermavant Submits Supplemental New Drug Application (sNDA) to FDA for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older [Yahoo! Finance]
Low
Report
Dermavant Submits Supplemental New Drug Application (sNDA) to FDA for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older [Yahoo! Finance]
2/13
07:11 am
roiv
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update [Yahoo! Finance]
Medium
Report
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update [Yahoo! Finance]
2/13
07:00 am
roiv
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
Low
Report
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
2/10
03:14 am
roiv
Roivant Sciences Ltd President & COO Eric Venker Sells 96,950 Shares [Yahoo! Finance]
Low
Report
Roivant Sciences Ltd President & COO Eric Venker Sells 96,950 Shares [Yahoo! Finance]
1/30
04:14 pm
roiv
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024 [Yahoo! Finance]
Low
Report
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024 [Yahoo! Finance]
1/30
04:05 pm
roiv
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
Low
Report
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
1/29
05:03 am
roiv
These are the 7 healthcare startups primed to IPO when the market reopens [Business Insider]
Low
Report
These are the 7 healthcare startups primed to IPO when the market reopens [Business Insider]